CS
PNT

Credit Suisse’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Credit Suisse’s Portfolio PNT Stock Details PNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-84,763
Closed -$565K – 3175
2023
Q3 		$565K Sell
84,763
-10,136
-11% -$84.2K ﹤0.01% 2611
2023
Q2 		$860K Buy
94,899
+35,198
+59% +$310K ﹤0.01% 2492
2023
Q1 		$434K Buy
59,701
+6,261
+12% +$46.4K ﹤0.01% 2820
2022
Q4 		$390K Buy
53,440
+24,973
+88% +$185K ﹤0.01% 2920
2022
Q3 		$220K Buy
28,467
+4,338
+18% +$36.8K ﹤0.01% 3211
2022
Q2 		$164K Buy
24,129
+1,001
+4% +$7.66K ﹤0.01% 3399
2022
Q1 		$184K Buy
23,128
+1,507
+7% +$9.57K ﹤0.01% 3391
2021
Q4 		$120K Buy
+21,621
New +$162K ﹤0.01% 4364

Other funds holding PNT

BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Credit Suisse's PNT Position: Q4 2023 in Review

Credit Suisse sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q4 2023, closing a stake of 84,763 shares — an estimated $565K sold.

Credit Suisse first reported a position in PNT in Q4 2021 and held it in 8 quarters. The position peaked at $860K in Q2 2023. 1 fund tracked by Wall St. Rank holds PNT as of Q4 2023.

  • Credit Suisse reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Credit Suisse sold 84,763 POINT Biopharma Global Inc. Common Stock shares in Q4 2023, an estimated $565K.
  • Credit Suisse first reported a position in POINT Biopharma Global Inc. Common Stock in Q4 2021 and held it in 8 quarters.
  • Credit Suisse's POINT Biopharma Global Inc. Common Stock position peaked at $860K in Q2 2023.
  • 1 fund tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q4 2023.

Based on Credit Suisse's 13F filing for Q4 2023, filed 8 Feb 2024.